April 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent
 

Tokyo, Jan 9, 2013 (JCN) - Chugai Pharmaceutical has granted Debiopharm Group an exclusive license to develop and commercialise FF284 in all countries worldwide including Japan. FF284, called Debio 1347 by Debiopharm, was discovered by Chugai and is about to start clinical development in oncology.

Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284. According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study.

Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Chugai News  
  Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent  (Jan 9, 2013)
  Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial  (Dec 16, 2008)
  DATA from Overseas Phase III Trial of "Actemra" a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients  (Oct 27, 2008)
  Roche to Raise Chugai Pharm Stake to 59.9 Percent  (May 23, 2008)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)



 Recent  Drugs & OTC News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)